A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

The phase 3 KEYNOTE‑B96 trial showed that Keytruda plus paclitaxel, with or without Avastin, improved overall survival in patients with platinum‑resistant ovarian cancer. From your perspective, what ...

MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.

CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. The research focused on 2 primary ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields ...